Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: Baseline results from the STABILITY study

European Journal of Preventive Cardiology

Volumn 20, Issue 4, 2013, Pages 678-685

  Vedin, Ola ^a   Hagström, Emil ^a   Stewart, Ralph ^b   Brown, Rebekkah ^c   Krug Gourley, Susan ^c   Davies, Richard ^c   Wallentin, Lars ^a   White, Harvey ^b   Held, Claes ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Cardiovascular risk factors; coronary heart disease; guideline recommendations; guidelines; secondary prevention

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OBESITY; PREVALENCE; PRIORITY JOURNAL; SMOKING;

CARDIOVASCULAR RISK FACTORS; CORONARY HEART DISEASE; GUIDELINE RECOMMENDATIONS; GUIDELINES; SECONDARY PREVENTION;

AGED; BENZALDEHYDES; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR AGENTS; CORONARY DISEASE; DOUBLE-BLIND METHOD; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPOLIPIDEMIC AGENTS; LIPIDS; MALE; MIDDLE AGED; OXIMES; PHOSPHOLIPASE A2 INHIBITORS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; SECONDARY PREVENTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84880282303     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/2047487312444995     Document Type: Article

References (20)

1. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004 ; 364 (9438). 937-952
2. Steg PG, Bhatt DL, Wilson PWF, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007 ; 297 (11). 1197-1206
3. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007 ; 14 (Suppl 2). S1 - S113
4. Smith SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006 ; 113 (19). 2363-2372
5. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J. 2001 ; 22 (7). 554-572
6. Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009 ; 16 (2). 121-137
7. De Velasco JA, Cosin J, Lopez-Sendon JL, et al. [New data on secondary prevention of myocardial infarction in Spain. Results of the PREVESE II study]. Rev Esp Cardiol. 2002 ; 55 (8). 801-809
8. Danchin N, Hanania G, Grenier O, et al. [Trends in discharge prescriptions for patients hospitalized for acute coronary syndromes in France from 1995 to 2000. Data from the Usik 1995, Prevenir 1, Prevenir 2 and Usic 2000 surveys]. Ann Cardiol Angeiol (Paris). 2003 ; 52 (1). 1-6
9. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006 ; 295 (2). 180-189
10. White H, Held C, Stewart R, et al. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. Am Heart J. 2010 ; 160 (4). 655-661
11. Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011 ; 377 (9765). 557-567
12. Alvarez LR, Balibrea JM, Surinach JM, et al. Smoking cessation and outcome in stable outpatients with coronary, cerebrovascular or peripheral artery disease. Eur J Cardiovasc Prev Rehabil. 2011 ;:
13. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009 ; 338: b1665 - b1665
14. Bartnik M, Ryden L, Ferrari R, et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J. 2004 ; 25 (21). 1880-1890
15. Standards of medical care in diabetes - 2011. Diabetes Care. 2011 ; 34 (Suppl 1). S11 - S61
16. Hu G, Jousilahti P, Qiao Q, et al. Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction. Diabetologia. 2005 ; 48 (5). 856-861
17. Gerstein HC, Miller ME, Genuth S, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011 ; 364 (9). 818-828
18. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 ; 376 (9753). 1670-1681
19. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011 ; 378 (9798). 1231-1243
20. Krumholz HM, Anderson JL, Bachelder BL, et al. ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American Academy of Family Physicians and American College of Emergency Physicians endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and Society of Hospital Medicine. J Am Coll Cardiol. 2008 ; 52 (24). 2046-2099